08:08 AM EST, 11/10/2025 (MT Newswires) -- Apogee Therapeutics ( APGE ) reported a Q3 net loss Monday of $1.11 per diluted share, widening from a loss of $0.86 a year earlier.

Three analysts polled by FactSet expected a loss of $1.15.

The company reported no revenue for the quarter ended Sept. 30.

Apogee Therapeutics ( APGE ) said its cash, cash equivalents, and marketable securities of $588.9 million as of Sept. 30 would be enough to fund operations into H2 2028.

Shares of the company were up 2.4% in recent premarket activity Monday.